Nothing Special   »   [go: up one dir, main page]

NO20052010D0 - Immunogen sammensetning - Google Patents

Immunogen sammensetning

Info

Publication number
NO20052010D0
NO20052010D0 NO20052010A NO20052010A NO20052010D0 NO 20052010 D0 NO20052010 D0 NO 20052010D0 NO 20052010 A NO20052010 A NO 20052010A NO 20052010 A NO20052010 A NO 20052010A NO 20052010 D0 NO20052010 D0 NO 20052010D0
Authority
NO
Norway
Prior art keywords
immunogenic composition
immunogenic
composition
Prior art date
Application number
NO20052010A
Other languages
English (en)
Other versions
NO20052010L (no
Inventor
Jean Stephenne
Yves Mayeresse
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32234471&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20052010(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0225520.6A external-priority patent/GB0225520D0/en
Priority claimed from GB0225543A external-priority patent/GB0225543D0/en
Priority claimed from GB0225532A external-priority patent/GB0225532D0/en
Priority claimed from GB0317381A external-priority patent/GB0317381D0/en
Priority claimed from GB0317371A external-priority patent/GB0317371D0/en
Priority claimed from GB0317380A external-priority patent/GB0317380D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of NO20052010D0 publication Critical patent/NO20052010D0/no
Publication of NO20052010L publication Critical patent/NO20052010L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20052010A 2002-11-01 2005-04-25 Immunogen sammensetning NO20052010L (no)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB0225520.6A GB0225520D0 (en) 2002-11-01 2002-11-01 Drying process
GB0225543A GB0225543D0 (en) 2002-11-01 2002-11-01 Immunogenic composition
GB0225532A GB0225532D0 (en) 2002-11-01 2002-11-01 Drying process
GB0317381A GB0317381D0 (en) 2003-07-24 2003-07-24 Drying method
GB0317371A GB0317371D0 (en) 2003-07-24 2003-07-24 Immunogenic composition
GB0317380A GB0317380D0 (en) 2003-07-24 2003-07-24 Drying method
PCT/EP2003/012160 WO2004039399A1 (en) 2002-11-01 2003-10-30 Immunogenic composition

Publications (2)

Publication Number Publication Date
NO20052010D0 true NO20052010D0 (no) 2005-04-25
NO20052010L NO20052010L (no) 2005-06-24

Family

ID=32234471

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20051998A NO342741B1 (no) 2002-11-01 2005-04-25 Fremgangsmåte for konservering av et aktivt agens, svært viskøs væske, immunogen sammensetning eller vaksine, fremgangsmåte for fremstilling av en vaksine samt kit.
NO20052010A NO20052010L (no) 2002-11-01 2005-04-25 Immunogen sammensetning
NO20180874A NO344759B1 (no) 2002-11-01 2018-06-21 Fremgangsmåte for konservering av et aktivt agens.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20051998A NO342741B1 (no) 2002-11-01 2005-04-25 Fremgangsmåte for konservering av et aktivt agens, svært viskøs væske, immunogen sammensetning eller vaksine, fremgangsmåte for fremstilling av en vaksine samt kit.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20180874A NO344759B1 (no) 2002-11-01 2018-06-21 Fremgangsmåte for konservering av et aktivt agens.

Country Status (28)

Country Link
US (3) US7927858B2 (no)
EP (3) EP2395073B1 (no)
JP (2) JP4579156B2 (no)
KR (2) KR101058978B1 (no)
AR (2) AR041881A1 (no)
AT (1) ATE352316T1 (no)
AU (2) AU2003278166B2 (no)
BR (1) BR0315767A (no)
CA (2) CA2503946C (no)
CY (2) CY1119504T1 (no)
DE (1) DE60311526T2 (no)
DK (2) DK1556477T3 (no)
ES (3) ES2649048T3 (no)
HK (1) HK1085380A1 (no)
HU (1) HUE034801T2 (no)
IL (2) IL168054A (no)
IS (2) IS3028B (no)
LT (2) LT1556477T (no)
MA (2) MA27551A1 (no)
MX (3) MX343419B (no)
MY (2) MY132859A (no)
NO (3) NO342741B1 (no)
NZ (2) NZ539613A (no)
PL (2) PL213647B1 (no)
PT (2) PT1556477T (no)
SI (2) SI1556477T1 (no)
TW (2) TWI332843B (no)
WO (2) WO2004039399A1 (no)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT1556477T (lt) * 2002-11-01 2017-10-25 Glaxosmithkline Biologicals S.A. Džiovinimo būdas
US20060099567A1 (en) * 2004-04-08 2006-05-11 Biomatrica, Inc. Integration of sample storage and sample management for life science
CN101035620B (zh) * 2004-04-08 2012-01-04 生物马特里卡公司 用于生命科学的样品存储和样品管理的综合
US20080176209A1 (en) * 2004-04-08 2008-07-24 Biomatrica, Inc. Integration of sample storage and sample management for life science
GB0409795D0 (en) * 2004-04-30 2004-06-09 Glaxosmithkline Biolog Sa Drying method
TWI398272B (zh) * 2005-03-08 2013-06-11 Intervet Int Bv 化學定義的安定劑
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
CA2612980C (en) 2005-06-27 2019-01-15 Glaxosmithkline Biologicals S.A. Immunogenic composition comprising a haemophilus influenzae type b saccharide conjugate
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
ES2470340T3 (es) 2005-12-28 2014-06-23 Advanced Bionutrition Corporation Vehículo de administración para bacterias probi�ticas que comprende una matriz seca de polisac�ridos, sac�ridos y polioles en forma vítrea
CA2662064A1 (en) 2006-09-07 2008-03-13 Glaxosmithkline Biologicals S.A. Method of producing a combination polivirus vaccine
EP2117354B1 (en) * 2006-12-18 2018-08-08 Advanced BioNutrition Corp. A dry food product containing live probiotic
TW200914042A (en) 2007-05-02 2009-04-01 Glaxosmithkline Biolog Sa Vaccine
KR101557169B1 (ko) * 2007-05-18 2015-10-02 메디뮨 엘엘씨 냉동 건조 발포체에 의한 생활성 물질의 보존
WO2008155529A1 (en) * 2007-06-16 2008-12-24 Enigma Diagnostics Limited Compositions
GB0711683D0 (en) * 2007-06-16 2007-07-25 Enigma Diagnostics Ltd Compositions
CN101801343A (zh) * 2007-07-26 2010-08-11 圣诺菲·帕斯图尔有限公司 抗原佐剂组合物及其方法
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
CA2756883C (en) 2009-03-27 2018-01-09 Advanced Bionutrition Corp. Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish
CA2763074C (en) 2009-05-26 2021-02-23 Moti Harel Stable dry powder composition comprising biologically active microorganisms and/or bioactive materials and methods of making
EP2475393A4 (en) * 2009-09-14 2013-08-21 Vu Truong-Le FORMULATION FOR THE ROOM TEMPERATURE STABILIZATION OF A WEAKED LIVING BACTERIAL VACCINE
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
SG182317A1 (en) 2010-01-28 2012-08-30 Advanced Bionutrition Corp Dry glassy composition comprising a bioactive material
FR2960781B1 (fr) 2010-06-07 2013-11-22 Sanofi Pasteur Preparation d'un vaccin oral sec stabilise, compose d'un virus vivant attenue
WO2012018639A2 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
US9376709B2 (en) 2010-07-26 2016-06-28 Biomatrica, Inc. Compositions for stabilizing DNA and RNA in blood and other biological samples during shipping and storage at ambient temperatures
DK2603100T3 (en) 2010-08-13 2018-08-06 Advanced Bionutrition Corp DRY STABILIZING COMPOSITION FOR STORAGE OF BIOLOGICAL MATERIALS
WO2012028315A1 (en) 2010-09-02 2012-03-08 Sanofi Pasteur Sa A stabilizer for the preparation of a dry polio injectable vaccine composition
WO2012075376A2 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Lyophilized viral formulations
US9045728B2 (en) 2010-12-02 2015-06-02 Oncolytics Biotech Inc. Liquid viral formulations
US20120222979A1 (en) 2011-03-04 2012-09-06 Elwha LLC, a limited liability company of the State of Delaware Glassy compositions
EP3058952A1 (en) * 2011-04-07 2016-08-24 Glaxosmithkline LLC Formulations with reduced viscosity
CA2832560A1 (en) * 2011-04-07 2012-10-18 Glaxosmithkline Llc Formulations with reduced viscosity
CA2777431A1 (en) 2011-05-20 2012-11-20 Nitto Denko Corporation Pharmaceutical composition and method for producing the same
MX354988B (es) 2011-10-25 2018-03-28 Prothena Biosciences Ltd Formulaciones de anticuerpo y metodos.
EP2934572A4 (en) 2012-12-20 2016-11-23 Biomatrica Inc FORMULATIONS AND METHODS FOR STABILIZING PCR REAGENTS
CN105530955A (zh) * 2013-10-03 2016-04-27 日东电工株式会社 流感疫苗干燥制剂、及流感疫苗干燥制剂的制造方法
JP6469698B2 (ja) * 2013-12-19 2019-02-13 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． ビロソーム製剤の改良
CN106413749B (zh) 2014-02-11 2022-04-05 麻省理工学院 新颖全谱抗登革抗体
ES2891555T3 (es) 2014-06-10 2022-01-28 Biomatrica Inc Estabilización de trombocitos a temperaturas ambiente
WO2016012385A1 (en) * 2014-07-21 2016-01-28 Sanofi Pasteur Vaccine composition comprising ipv and cyclodextrins
WO2017001590A1 (en) 2015-06-30 2017-01-05 Nestec S.A. Composition suitable for protecting microorganisms
JP6889699B2 (ja) 2015-07-29 2021-06-18 アドバンスド バイオニュートリション コープ． 特定栄養用途のための安定乾燥プロバイオティクス組成物
BR112018004400A2 (pt) * 2015-09-04 2018-12-04 Inventprise Llc composições de vacina vlp estabilizadas
SG11201804776SA (en) 2015-12-08 2018-07-30 Biomatrica Inc Reduction of erythrocyte sedimentation rate
PT3506935T (pt) 2016-09-02 2024-04-01 Sanofi Pasteur Inc Vacina contra neisseria meningitidis
EP3781192A1 (en) * 2018-04-16 2021-02-24 Merck Patent GmbH Additives for protein formulations to improve thermal stability
CA3112902A1 (en) * 2018-09-28 2020-04-02 Otsuka Pharmaceutical Factory, Inc. Mammal cell preserving solution containing acarbose or stachyose

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US509893A (en) * 1893-12-05 William griesser
DE1157734B (de) 1961-08-16 1963-11-21 Behringwerke Ag Verfahren zur Herstellung von haltbaren, oral zu verabreichenden Poliomyelitisvirus-Praeparaten
US3767790A (en) 1972-02-11 1973-10-23 Nat Patent Dev Corp Microorganisms
US3929132A (en) * 1973-04-10 1975-12-30 Alza Corp Osmotic dispenser
DE3071552D1 (en) 1979-09-21 1986-05-22 Hitachi Ltd Semiconductor switch
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
GB8323094D0 (en) * 1983-08-26 1983-09-28 Franks F Preservation of cells
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
JPH0779694B2 (ja) 1985-07-09 1995-08-30 カドラント バイオリソ−シズ リミテツド 蛋白質および同類品の保護
GB8604983D0 (en) * 1986-02-28 1986-04-09 Biocompatibles Ltd Protein preservation
GB8715238D0 (en) 1987-06-29 1987-08-05 Quadrant Bioresources Ltd Food process
GB8801338D0 (en) * 1988-01-21 1988-02-17 Quadrant Bioresources Ltd Preservation of viruses
DE3819530A1 (de) * 1988-06-08 1989-12-21 Westphal Geb Jauch Christel Dr Verfahren, traeger und testsatz fuer die kultivierung und mikroskopische untersuchung von zellen
ATE205534T1 (de) 1988-12-16 2001-09-15 Nederlanden Staat Pneumolysin-mutanten und pneumokokken-impfstoffe daraus
ZA907737B (en) 1989-09-29 1991-07-31 Nisshin Oil Mills Ltd Stable immunogen composition for oral administration
JPH03161441A (ja) 1989-11-20 1991-07-11 Senjiyu Seiyaku Kk メイラード反応阻害剤
EP1338607A3 (en) 1990-07-16 2004-08-18 University Of North Carolina At Chapel Hill Antigenic iron repressible proteins from n. meningitidis related to the heolysin family of toxins
US5912336A (en) 1990-08-23 1999-06-15 University Of North Carolina At Chapel Hill Isolated nucleic acid molecules encoding transferrin binding proteins from Neisseria gonorrhoeae and Neisseria meningitidis
DK0546118T3 (da) 1990-08-23 2004-02-16 Univ North Carolina Transferrinbindende proteiner fra Neisseria gonorrhoeae og Neisseria meningtidis
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
FR2682041B1 (fr) 1991-10-03 1994-01-14 Pasteur Merieux Serums Vaccins Vaccin contre les infections a neisseria meningitidis.
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
CA2129899C (en) 1992-02-11 2011-01-04 James J. Mond Dual carrier immunogenic construct
AU3630093A (en) 1992-03-02 1993-10-05 Biocine S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
DK0835663T3 (da) 1992-05-23 2010-02-01 Glaxosmithkline Biolog Sa Kombinerede vacciner omfattende Hepatitis B overfladeantigen og andre antigener
FR2692592B1 (fr) 1992-06-19 1995-03-31 Pasteur Merieux Serums Vacc Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant.
ATE176157T1 (de) 1992-10-27 1999-02-15 American Cyanamid Co Pädiatrische kombinationsvakzine mit verbesserter immunogenizität jeder vakzine komponente
WO1994026304A1 (en) 1993-05-18 1994-11-24 Ohio State Research Foundation Otitis media vaccine
CN1158572A (zh) 1994-08-09 1997-09-03 日清制油株式会社 经口用免疫原组合物及其制造方法
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6265567B1 (en) 1995-04-07 2001-07-24 University Of North Carolina At Chapel Hill Isolated FrpB nucleic acid molecule
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
AU695720B2 (en) 1995-06-07 1998-08-20 Smithkline Beecham Biologicals (Sa) Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein
CA2223438C (en) * 1995-06-07 2008-05-13 Quadrant Holdings Cambridge Limited Methods for stably incorporating substances within dry, foamed glass matrices and compositions obtained thereby
EP0832238A1 (en) 1995-06-07 1998-04-01 Biochem Vaccines Inc. Streptococcal heat shock proteins members of the hsp70 family
DK0833662T4 (da) 1995-06-23 2011-02-28 Smithkline Beecham Biolog Vaccinepræparat omfattende et Haemophilus influenza B-polysaccharidkonjugatantigen adsorberet på aluminiumphosphat
DE19543770C2 (de) 1995-11-24 1998-11-05 Metallgesellschaft Ag Vorrichtung zur Messung von kondensierter Feuchtigkeit in Vorrichtungen und/oder Rohrleitungen der chemischen Technik und deren Verwendung
AU1671197A (en) * 1996-02-13 1997-09-02 Nisshin Oil Mills, Ltd., The Vaccine-containing emulsion and vaccine-containing powder for oral administration and process for producing the same
ATE323721T1 (de) 1996-05-01 2006-05-15 Univ Rockefeller Cholin-bindendes protein, welches als gegen pneumokokken gerichtetes vakzin verwendet wird
US5766520A (en) 1996-07-15 1998-06-16 Universal Preservation Technologies, Inc. Preservation by foam formation
CA2256333A1 (en) * 1996-05-29 1997-12-04 Victor Bronshtein Long-term shelf preservation by vitrification
DE69736709T2 (de) * 1996-07-02 2007-10-04 Sanofi Pasteur Ltd., Toronto Vielwertige dtp-polio-impfstoffe
FR2751000B1 (fr) 1996-07-12 1998-10-30 Inst Nat Sante Rech Med Adn specifiques des bacteries de l'espece neisseria meningitidis, leurs procedes d'obtention et leurs applications biologiques
DE19630390A1 (de) 1996-07-26 1998-01-29 Chiron Behring Gmbh & Co Proteine, insbesondere Membranproteine von Helicobacter pylori, ihre Herstellung und Verwendung
US5882896A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
US5882871A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
ATE348887T1 (de) 1996-10-31 2007-01-15 Human Genome Sciences Inc Streptococcus pneumoniae antigene und impfstoffe
US6051238A (en) * 1996-12-20 2000-04-18 Merck & Co., Inc. Stabilizers for lyophilized mumps vaccines
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
SE511963C2 (sv) 1997-04-23 1999-12-20 Ericsson Telefon Ab L M Anordning och förfarande för bestämning av linjespänning i en abonnentlinjekrets
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
EP0998557A2 (en) 1997-07-21 2000-05-10 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
ATE316797T1 (de) * 1997-09-15 2006-02-15 Sanofi Pasteur Msd Verfahren zur herstellung multivalenter impfstoffe
ATE352624T1 (de) 1997-11-21 2007-02-15 Serono Genetics Inst Sa Chlamydia pneumoniae genomische sequenzen und polypeptiden, fragmenten und anwendungen davon für nachweis, prevention und heilung
JP2001524306A (ja) * 1997-11-26 2001-12-04 ユニバーサル プリザーベーション テクノロジーズ インコーポレイテッド ガラス化による不安定な生物学的サンプルの保存
KR100735652B1 (ko) 1997-11-28 2007-07-06 세로노 제네틱스 인스티튜트 에스.에이. 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
GB9726398D0 (en) 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
BR9906927A (pt) 1998-01-14 2001-11-20 Chiron Spa Proteìnas de neisseria meningitidis
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
ES2343492T3 (es) 1998-04-07 2010-08-02 Medimmune, Llc Derivados de proteinas neumococicas de union a colina para vacunas.
GB9807721D0 (en) 1998-04-08 1998-06-10 Chiron Spa Antigen
EP2261345A3 (en) 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
US6306345B1 (en) 1998-05-06 2001-10-23 Universal Preservation Technologies, Inc. Industrial scale barrier technology for preservation of sensitive biological materials at ambient temperatures
BR9914374A (pt) 1998-10-09 2002-09-17 Chiron Corp Sequências genÈmicas de neisseria e métodos para seu uso
DK1535928T3 (da) 1998-10-22 2008-10-20 Univ Montana Vaccinesammensætninger indeholdende Omp85-proteiner af Neisseria gonorrhoeae og Neisseria meningitidis
CA2350775A1 (en) 1998-11-12 2000-05-18 The Regents Of The University Of California Chlamydia pneumoniae genome sequence
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
AU750762B2 (en) 1999-03-19 2002-07-25 Smithkline Beecham Biologicals (Sa) Vaccine
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
JP2002541808A (ja) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア
PT1233784E (pt) 1999-12-02 2008-11-03 Novartis Vaccines & Diagnostic Composições e métodos para a estabilização de moléculas biológicas após a liofilização
PT2289545T (pt) 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
ES2386534T3 (es) 2000-02-28 2012-08-22 Novartis Vaccines And Diagnostics S.R.L. Expresión heteróloga de proteínas de Neisseria
SK288007B6 (sk) * 2000-06-29 2012-10-02 Glaxosmithkline Biologicals S. A. Multivalent vaccine composition, process for its producing, and its use
ATE440861T1 (de) 2000-07-03 2009-09-15 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia pneumoniae
KR100385711B1 (ko) * 2000-07-05 2003-05-27 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드와 백일해균 및ｂ형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법
NZ560966A (en) 2000-10-27 2010-06-25 Novartis Vaccines & Diagnostic Nucleic acids and proteins from streptococcus groups A & B
RU2323002C2 (ru) 2001-07-26 2008-04-27 Чирон Срл. Вакцины, содержащие алюминиевые адъюванты и гистидин
EP1494651A4 (en) * 2002-04-11 2010-10-13 Medimmune Vaccines Inc PRESERVATION OF BIO-ACTIVE MATERIALS WITH LYOPHILIZED FOAM
LT1556477T (lt) * 2002-11-01 2017-10-25 Glaxosmithkline Biologicals S.A. Džiovinimo būdas
GB0409795D0 (en) * 2004-04-30 2004-06-09 Glaxosmithkline Biolog Sa Drying method
US9473463B2 (en) 2014-07-29 2016-10-18 Combined Conditional Access Development & Support, LLC Control word and associated entitlement control message caching and reuse

Also Published As

Publication number Publication date
DK1556477T3 (en) 2017-10-23
EP1575612A1 (en) 2005-09-21
IS3028B (is) 2021-05-15
MX343419B (es) 2016-11-04
EP2395073B1 (en) 2017-09-06
JP2006504801A (ja) 2006-02-09
US20060127414A1 (en) 2006-06-15
IS7806A (is) 2005-04-18
LT1556477T (lt) 2017-10-25
WO2004039399A1 (en) 2004-05-13
CY1119362T1 (el) 2018-03-07
JP4579156B2 (ja) 2010-11-10
PT1556477T (pt) 2017-11-14
US8409587B2 (en) 2013-04-02
NO20052010L (no) 2005-06-24
IL168052A0 (en) 2011-08-01
AR041881A1 (es) 2005-06-01
ATE352316T1 (de) 2007-02-15
DK2395073T3 (en) 2017-10-23
CA2503871C (en) 2012-12-11
ES2649048T3 (es) 2018-01-09
KR20050075766A (ko) 2005-07-21
IS7805A (is) 2005-04-18
TW200501980A (en) 2005-01-16
NO20180874A1 (no) 2005-06-24
LT2395073T (lt) 2017-11-10
KR20050084626A (ko) 2005-08-26
CA2503946A1 (en) 2004-05-13
AU2003287980A1 (en) 2004-05-25
TW200501981A (en) 2005-01-16
PL213647B1 (pl) 2013-04-30
NZ539613A (en) 2008-09-26
EP1556477B1 (en) 2017-08-09
MA27644A1 (fr) 2005-12-01
WO2004039417A2 (en) 2004-05-13
NO20051998D0 (no) 2005-04-25
CY1119504T1 (el) 2018-03-07
PL215237B1 (pl) 2013-11-29
HK1085380A1 (en) 2006-08-25
NZ539706A (en) 2008-03-28
ES2645924T3 (es) 2017-12-11
US20110159038A1 (en) 2011-06-30
ES2280809T3 (es) 2007-09-16
WO2004039417A3 (en) 2004-12-16
AR041880A1 (es) 2005-06-01
DE60311526T2 (de) 2007-10-31
AU2003287980B2 (en) 2009-06-25
EP2395073A3 (en) 2012-01-25
KR101130948B1 (ko) 2012-03-30
PL376950A1 (pl) 2006-01-09
NO342741B1 (no) 2018-08-06
SI1556477T1 (sl) 2017-12-29
PL377170A1 (pl) 2006-01-23
MXPA05004528A (es) 2005-07-26
AU2003278166B2 (en) 2009-01-29
DE60311526D1 (de) 2007-03-15
CA2503871A1 (en) 2004-05-13
TWI332843B (en) 2010-11-11
EP1556477A2 (en) 2005-07-27
HUE034801T2 (en) 2018-02-28
IL168052A (en) 2015-03-31
MA27551A1 (fr) 2005-10-03
AU2003278166A1 (en) 2004-05-25
NO344759B1 (no) 2020-04-14
US7927858B2 (en) 2011-04-19
EP1575612B1 (en) 2007-01-24
MXPA05004675A (es) 2005-06-08
BR0315767A (pt) 2005-09-06
MY132859A (en) 2007-10-31
SI2395073T1 (sl) 2017-12-29
JP2006512406A (ja) 2006-04-13
US8449865B2 (en) 2013-05-28
IL168054A (en) 2011-06-30
PT2395073T (pt) 2017-11-24
NO20051998L (no) 2005-06-24
EP2395073A2 (en) 2011-12-14
US20060127415A1 (en) 2006-06-15
CA2503946C (en) 2016-08-16
KR101058978B1 (ko) 2011-08-23
MY145693A (en) 2012-03-30

Similar Documents

Publication Publication Date Title
NO20052010D0 (no) Immunogen sammensetning
IS7547A (is) Ónæmisvaldandi samsetningar
ATE553775T1 (de) Impstoffzusammesetzung
NO20050132D0 (no) Vaksinesammensetning
FR13C0072I1 (fr) Nouvelle composition de vaccin
NO20026175L (no) Vaksinesammensetning
IS8387A (is) Ónæmisvaldandi samsetningar
ATE490327T1 (de) Impfstoffzusammensetzung
DK1896062T3 (da) Immunogen sammensætning
ATE390898T1 (de) Zwischenwirbelimplantat
ATE394087T1 (de) Zwischenwirbelimplantat
ATE394086T1 (de) Zwischenwirbelimplantat
DE10393374D2 (de) Zusammensetzung
DK1427444T3 (da) West-nil-vaccine
BR0210619A (pt) composição
IS7081A (is) Lyfjablanda
NO20033882D0 (no) Vaksine
IS7831A (is) Bóluefni
SE0500163L (sv) Sammansättning
DE60328408D1 (de) Impfstoff
NO20051561D0 (no) Vaksine
ITTO20020744A0 (it) Composizione
AU2003250828A8 (en) Immunogenic compositions
GB0225543D0 (en) Immunogenic composition
ITTO20020746A0 (it) Composizione

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application